GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » Loans Receivable

JBM (Healthcare) (HKSE:02161) Loans Receivable : HK$0.0 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) Loans Receivable?

JBM (Healthcare)'s Loans Receivable for the quarter that ended in Sep. 2024 was HK$0.0 Mil.


JBM (Healthcare) Loans Receivable Historical Data

The historical data trend for JBM (Healthcare)'s Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JBM (Healthcare) Loans Receivable Chart

JBM (Healthcare) Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Loans Receivable
Get a 7-Day Free Trial - - - - -

JBM (Healthcare) Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

JBM (Healthcare) Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


JBM (Healthcare) Loans Receivable Related Terms

Thank you for viewing the detailed overview of JBM (Healthcare)'s Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


JBM (Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
Executives
Sum Kwong Yip, Derek
Queenshill Development Limited
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited 2101 Beneficial owner
Gavett Limited 2201 Interest of corporation controlled by you
United Islands Group Limited 2201 Interest of corporation controlled by you
Fortstar Limited 2201 Interest of corporation controlled by you
Tao Richard 2201 Interest of corporation controlled by you
Hon Hing Tong Patricia 2202 Interest of your spouse
Tao Paul 2201 Interest of corporation controlled by you
Choi Siu Ping 2202 Interest of your spouse
Longjin Investments Limited 2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines